SeaStar Medical Holding Corp
ICU0.802USD
+0.002+0.21%
Market hours （ET）Quotes delayed by 15 min
13.90MMarket Cap
LossP/E TTM
More Details of SeaStar Medical Holding Corp Company
SeaStar Medical Holding Corporation is a commercial-stage medical technology company. The Company is focused on developing extracorporeal therapies to reduce the consequences of hyperinflammation on vital organs. The Company's technologies rely on science to provide life-saving solutions to critically ill patients. The Company develops and commercializes cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company uses its Selective Cytopheretic Device (SCD) technology platform to clinically validate several acute organ injury indications, including kidneys and lungs. Its investigational SCD is an extracorporeal synthetic membrane device designed to integrate into existing continuous renal replacement therapy (CRRT) systems that are commonly installed in hospitals throughout the United States.
Company Info
Ticker SymbolICU
Company nameSeaStar Medical Holding Corp
IPO dateJan 26, 2021
CEOMr. Eric Schlorff
Number of employees19
Security typeOrdinary Share
Fiscal year-endJan 26
Address3513 Brighton Blvd
CityDENVER
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code80216
Phone18444278100
Websitehttps://seastarmedical.com
Ticker SymbolICU
IPO dateJan 26, 2021
CEOMr. Eric Schlorff
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. John Neuman
Mr. John Neuman
Independent Director
Independent Director
82.67K
-1.59%
Mr. Eric Schlorff
Mr. Eric Schlorff
Chief Executive Officer, Interim Chief Financial Officer, Treasurer, Director
Chief Executive Officer, Interim Chief Financial Officer, Treasurer, Director
55.18K
--
Dr. Kevin Chung, M.D.
Dr. Kevin Chung, M.D.
Chief Medical Officer
Chief Medical Officer
23.18K
--
Ms. Jennifer A. (Jen) Baird
Ms. Jennifer A. (Jen) Baird
Independent Chairman of the Board
Independent Chairman of the Board
22.67K
-5.55%
Ms. Bernadette N. Vincent
Ms. Bernadette N. Vincent
Independent Director
Independent Director
2.67K
-33.33%
Mr. Kenneth (Ken) Van Heel
Mr. Kenneth (Ken) Van Heel
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Neuman
Mr. John Neuman
Independent Director
Independent Director
82.67K
-1.59%
Mr. Eric Schlorff
Mr. Eric Schlorff
Chief Executive Officer, Interim Chief Financial Officer, Treasurer, Director
Chief Executive Officer, Interim Chief Financial Officer, Treasurer, Director
55.18K
--
Dr. Kevin Chung, M.D.
Dr. Kevin Chung, M.D.
Chief Medical Officer
Chief Medical Officer
23.18K
--
Ms. Jennifer A. (Jen) Baird
Ms. Jennifer A. (Jen) Baird
Independent Chairman of the Board
Independent Chairman of the Board
22.67K
-5.55%
Ms. Bernadette N. Vincent
Ms. Bernadette N. Vincent
Independent Director
Independent Director
2.67K
-33.33%
Mr. Kenneth (Ken) Van Heel
Mr. Kenneth (Ken) Van Heel
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
UBS Financial Services, Inc.
0.33%
Neuman (John)
0.30%
Geode Capital Management, L.L.C.
0.25%
XTX Markets LLC
0.22%
The Vanguard Group, Inc.
0.21%
Other
98.70%
Shareholders
Shareholders
Proportion
UBS Financial Services, Inc.
0.33%
Neuman (John)
0.30%
Geode Capital Management, L.L.C.
0.25%
XTX Markets LLC
0.22%
The Vanguard Group, Inc.
0.21%
Other
98.70%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.98%
Individual Investor
0.79%
Investment Advisor/Hedge Fund
0.29%
Venture Capital
0.22%
Research Firm
0.20%
Bank and Trust
0.02%
Other
97.50%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
64
1.04M
4.18%
+532.11K
2025Q1
64
1.12M
9.53%
+609.78K
2024Q4
56
403.35K
5.53%
-59.49K
2024Q3
101
532.19K
15.84%
-408.40K
2024Q2
105
549.58K
17.81%
-317.45K
2024Q1
106
490.37K
46.99%
-245.21K
2023Q4
100
525.53K
64.26%
-360.30K
2023Q3
92
529.03K
69.17%
-298.51K
2023Q2
88
487.42K
67.26%
-347.45K
2023Q1
83
499.78K
93.97%
-289.56K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Neuman (John)
80.00K
0.5%
+40.00K
+100.00%
Jun 24, 2025
Geode Capital Management, L.L.C.
74.64K
0.46%
+29.21K
+64.30%
Mar 31, 2025
XTX Markets LLC
12.31K
0.08%
+12.31K
--
Mar 31, 2025
The Vanguard Group, Inc.
57.50K
0.36%
-33.91K
-37.10%
Mar 31, 2025
Schlorff (Eric)
33.52K
0.21%
+11.00
+0.03%
Jun 12, 2025
Tyche Wealth Partners LLC
37.70K
0.23%
+37.70K
--
Mar 31, 2025
Raymond James Financial Services Advisors, Inc.
32.26K
0.2%
+32.26K
--
Mar 31, 2025
Chung (Kevin)
18.18K
0.11%
-2.00
-0.01%
Jun 12, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 06, 2024
Merger
25<1
Jun 06, 2024
Merger
25<1
Jun 06, 2024
Merger
25<1
Jun 06, 2024
Merger
25<1
Date
Type
Ratio
Jun 06, 2024
Merger
25<1
Jun 06, 2024
Merger
25<1
Jun 06, 2024
Merger
25<1
Jun 06, 2024
Merger
25<1
